These are top 10 stocks traded on the Robinhood UK platform in July
On Friday, H.C. Wainwright & Co. reiterated their Buy rating on scPharmaceuticals (NASDAQ:SCPH) with a steady price target of $18.00. The firm’s analyst highlighted the recent label expansion of Furoscix to include the treatment of edema in adults with chronic kidney disease (CKD), including those with nephrotic syndrome. This approval by the Food and Drug Administration (FDA) significantly broadens the drug’s market potential, now estimated to increase scPharmaceuticals’ total addressable market by approximately $3 billion. InvestingPro analysis indicates the company’s revenue is expected to grow by 167% this year, with a strong liquidity position reflected in its current ratio of 8.08.
The expanded label, which came after last August’s extension to Class IV heart failure patients, was largely in line with the company’s requests and consistent with other intravenous and oral furosemide medications. scPharmaceuticals’ management has expressed satisfaction with the FDA’s decision and plans to start promoting the new label to nephrologists immediately. The company has been preparing for this expansion, having increased its sales force last September in anticipation of the growth in promotional activities for Furoscix. Based on InvestingPro’s Fair Value analysis, the stock appears undervalued at current levels, with multiple growth catalysts ahead. Subscribers can access the comprehensive Pro Research Report for detailed insights into the company’s growth trajectory and financial health metrics.
scPharmaceuticals is set to begin a targeted promotional campaign next week, followed by a launch meeting to train representatives on the new promotional materials before the full product launch scheduled for mid-April. The sales team, which was expanded in response to the drug’s promotional sensitivity, currently has access to approximately 400 doctors and is expected to extend its reach to about 4,500 doctors on its targeting list soon.
The analyst’s affirmation of the Buy rating and price target reflects confidence in the company’s strategy and the expanded market opportunity for Furoscix. The expanded indication is seen as a substantial step forward for scPharmaceuticals in addressing a larger patient population and driving the company’s growth.
In other recent news, scPharmaceuticals Inc. has announced its preliminary financial results for the fourth quarter and full year of 2024. The company anticipates fourth-quarter net revenue to be between $12 million and $12.3 million, reflecting a significant 99% increase compared to the same period in 2023. For the entire year, scPharmaceuticals expects net revenue to range from $36.2 million to $36.5 million, marking a substantial 167% increase from the $13.6 million reported for 2023. This growth is largely attributed to the company’s expansion efforts, including partnerships with Integrated Delivery Networks and hospital systems, and an expanded field sales force. The gross-to-net discount for the fourth quarter is projected to be between 18% and 19%, up from 15.7% in the third quarter of 2024. Additionally, scPharmaceuticals shipped approximately 13,300 doses of FUROSCIX in the fourth quarter, a 23% increase from the previous quarter. The company’s cash and cash equivalents were reported at approximately $75.7 million as of December 31, 2024, excluding a 27% increase in accounts receivable since September 30, 2024. The company plans to report its final and complete financial results for the fourth quarter and full year of 2024 in March 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.